Taking this into account, H.C. Wainwright initiated its ImmunityBio Inc [IBRX] rating to a Buy in a research note published on March 06, 2025; the price target was $8. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Piper Sandler also remained covering IBRX and has decreased its forecast on May 12, 2023 with a “Neutral” recommendation from previously “an Overweight” rating. Jefferies started covering the stock on August 03, 2022. It rated IBRX as “a Buy”.
Price Performance Review of IBRX
On Monday, ImmunityBio Inc [NASDAQ:IBRX] saw its stock jump 14.01% to $2.36. Over the last five days, the stock has gained 12.38%. ImmunityBio Inc shares have fallen nearly -7.81% since the year began. Nevertheless, the stocks have fallen -70.20% over the past one year. While a 52-week high of $9.16 was reached on 02/19/25, a 52-week low of $1.83 was recorded on 05/07/25. SMA at 50 days reached $2.69, while 200 days put it at $3.56.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 2.22, which if violated will result in even more drops to 2.08. On the upside, there is a resistance level at 2.48. A further resistance level may holdings at 2.60. The Relative Strength Index (RSI) on the 14-day chart is 46.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 49.04%. Stochastics %K at 33.01% indicates the stock is a holding.
